New sepsis guideline targets faster, tailored treatments to benefit patients
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
Five smart technologies that act as a "second pair of eyes" during bowel examinations have been conditionally recommended by NICE for NHS use, potentially helping doctors spot harmful growths that could turn into cancer.
Our landmark review demonstrates a new approach to keeping NHS care up-to-date and could benefit thousands of adults with metastatic prostate cancer.
People living with metastatic prostate cancer in England will gain access to a new treatment combination from today (Friday, 24 October), following a recommendation by NICE.
NICE is poised to deliver key commitments in the government’s 10 Year Plan for health and care. We’re delighted by the plan’s endorsement of our role in delivering faster, and fairer access to the best innovations. It will strengthen our position in the system, guided by our core purpose.
Our annual report and accounts summarise our key achievements from April 2024 to March 2025.
For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.
